GordonMD Global Investments LP — 13F Portfolio

GordonMD Global Investments LP is an investment manager that files Form 13F with the SEC under CIK #0002039349. Form 13F is a quarterly disclosure of long positions in U.S.-listed “13F securities” (generally listed equities, certain ADRs, and many ETFs) as of the quarter-end date. For allocator diligence, this creates an auditable trail of the firm’s publicly disclosed long public-equity exposure. The “LP” legal form is consistent with a private investment partnership structure. The 13F record, however, should be treated as a partial-view dataset: it typically does not include short positions, many derivatives, cash balances, or non-reportable instruments. As a result, a 13F-based read-through is best framed as “the disclosed long book,” not the firm’s total portfolio construction. The manager’s business address and signing individual are usually present on the Form 13F cover page and/or in the SEC submission metadata. Because those fields were not provided in the request, location and named leadership are not asserted here and should be verified directly against the filings associated with CIK #0002039349.

The most supportable strategy description from public data begins with what the firm must disclose: quarter-end long holdings in U.S.-listed reportable securities. The name “Global Investments” suggests an unconstrained opportunity set, but the 13F lens will only capture the U.S.-listed component (including ADR implementation where applicable). Allocator-relevant characteristics that can be underwritten directly from the 13F history include: - Concentration and conviction: whether the disclosed book is built around a small number of core positions or a broad roster of smaller weights. - Implementation preference: use of single-name equities versus ETFs as exposure carriers. - Geographic expression through U.S.-listed instruments: reliance on domestic issuers versus ADRs/U.S.-listed vehicles to express non-U.S. exposure. - Persistence of exposures: whether the firm maintains stable “core” positions across many quarters or frequently reconstitutes the book. Within the platform, the cleanest starting point is Sector Allocation History to determine whether exposures cluster structurally (e.g., persistent technology/health care tilt) or rotate meaningfully across regimes. A Portfolio Simulator / Backtesting Service can then be used to replicate the disclosed long sleeve (a “13F History” holdings-replication) to study capital trajectory—explicitly acknowledging that this is not a full-fund replication when shorts/derivatives or non-13F assets are meaningful.

What is publicly anchorable: - GordonMD Global Investments LP is a Form 13F filing manager with the SEC under CIK #0002039349. - The 13F dataset provides quarter-end transparency into long U.S.-listed equity/ETF/ADR positions that meet 13F reporting criteria. What can be concluded (and what cannot) from 13F alone: - Underwriteable from filings: concentration, holdings stability, sector/factor posture, and the direction of quarter-to-quarter repositioning. - Not underwriteable from filings alone: net exposure, the presence/size of short books, derivative overlays, and non-reportable asset allocation. Secondary analytics (scoped to the disclosed sleeve) that are typically most decision-useful include a replicated Simulated Growth Chart and comparative diagnostics such as Alpha Generation vs S&P 500, with all results interpreted as holdings-based historical replication of reported longs. Diagnostic regime question: in periods when equity correlations rise and dispersion falls (beta-dominated tape), does the firm’s disclosed 13F positioning become more benchmark-like, or does it maintain concentrated idiosyncratic exposures that imply conviction in security selection through that regime?

Risk assessment for GordonMD Global Investments LP should begin with two constraints: 1) Disclosure constraint: 13F is long-only (in most cases) and quarterly, which can mask hedging, leverage, or intra-quarter trading. 2) Sleeve definition: any replication or risk statistic derived from filings describes the disclosed long public-equity sleeve, not necessarily the firm’s net exposure. Within the disclosed sleeve, the primary risk drivers typically observable are: - Market and factor sensitivity: exposure to equity beta, style factors (growth/value), and cyclical/defensive positioning inferred from holdings. - Concentration risk: drawdowns can be dominated by a few holdings if weights are high. - Liquidity and gap risk: smaller-cap or event-sensitive names (if present) can introduce discontinuous moves that are not well-described by average volatility. A holdings-replication can be used to estimate Max Drawdown Depth for the disclosed sleeve and to evaluate whether outcomes were dominated by broad beta or by idiosyncratic selection and sizing.